Back to Journals » Pediatric Health, Medicine and Therapeutics » Volume 10

An open-label, randomized prospective study to evaluate the efficacy and safety of Carica papaya leaf extract for thrombocytopenia associated with dengue fever in pediatric subjects

Authors Srikanth BK, Reddy L, Biradar S, Shamanna M, Mariguddi DD, Krishnakumar M

Received 9 June 2018

Accepted for publication 14 November 2018

Published 17 January 2019 Volume 2019:10 Pages 5—11

DOI https://doi.org/10.2147/PHMT.S176712

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Roosy Aulakh


BK Srikanth,1 Lakshminarayana Reddy,1 Sunita Biradar,1 Manjula Shamanna,2 Deepak D Mariguddi,2 M Krishnakumar2

1Department of Paediatrics, Vijayanagara Institute of Medical Sciences, Bellary, Karnataka, India; 2Department of Medical Services, Micro Labs Ltd, Bengaluru, Karnataka, India

Objective: Thrombocytopenia in dengue fever (DF) is a well-known complication in both adults and pediatric subjects. Management of DF primarily includes symptomatic and intensive supportive care. There are studies available on the efficacy and safety of Carica papaya leaf extract (CPLE) in adult patients with DF. However, there are no published studies available on the efficacy and safety of CPLE in the pediatric age group. Hence, this study was conducted.
Methodology: A prospective, open-label, randomized controlled study was conducted in subjects aged between 1 and 12 years having thrombocytopenia associated with DF (NS-1 antigen positive) or dengue hemorrhagic fever (DHF) grades I and II. All participants were randomized into the intervention group (n =147, CPLE syrup + standard therapy) and the control group (n=147, received only standard therapy). All subjects were followed up daily for 5 days with monitoring of blood counts.
Results: A total of 285 subjects were finally evaluated for efficacy, and nine dropped out (seven in the control group and two in the intervention group). However, all 294 subjects were evaluated for safety. CPLE (Caripill) syrup increased the platelet count significantly compared to the control group (P<0.05). In the intervention group, the platelet count increased from day 3 onward: platelet count on day 3 (mean platelet count =89,739.31, P=0.030), day 4 (mean platelet count =120,788.96, P=0.019), and day 5 (mean platelet count =168,922.75 P=0.023). Two children complained of nausea in the intervention group. Overall, Caripill syrup was well tolerated.
Conclusion: CPLE syrup significantly increases the platelet count in pediatric DF patients and is well tolerated.

Keywords: Caripill, viral fever, platelet, children, syrup, India

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]